Exhibit 99.1

Investor Event November 16, 2021

Forward Looking Statement and Non-GAAP Financial Information 2 This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the Company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available on the SEC’s website, on the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.This presentation includes certain non-generally accepted accounting principles (GAAP) financial measures that we use to describe our company’s performance. The non-GAAP information presented provides investors with additional useful information but should not be considered in isolation or as substitutes for the related GAAP measures. Moreover, other companies may define non-GAAP measures differently, which limits the usefulness of these measures for comparisons with such other companies. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable GAAP financial measure are available on our website at bms.com/investors. Also note that a reconciliation of certain forward-looking statements, however, is not provided due to no reasonably accessible or reliable comparable GAAP measures for such statements and the inherent difficulty in forecasting and quantifying such statements that are necessary for such reconciliation.

Today’s Agenda 3 Rupert Vessey Samit Hirawat Chris Boerner David Elkins Giovanni Caforio Strategic Overview Innovation Engine & Early Pipeline Late-Stage Pipeline Update Commercial Opportunities Financial Overview BREAK (10 min) Giovanni Caforio Closing, Q&A Conclusion, lunch reception 12:00 pm

Giovanni CaforioBoard Chair and Chief Executive Officer Strategic Overview

A differentiated biopharma company focused on innovative medicines for patients with cancer and other serious diseases BEST OF BIOTECHBEST OF PHARMA Leading scientific innovationCollaborating at center of the biotech ecosystemLeveraging global scale and agilityDriven by the best people 5 Our strategic foundation

Diabetes business divested, e.g. Creating our biopharma company Focusing on specialty medicines Deepening our innovation engine& long-term growth drivers BioPharma Strategyintroduced 2013 2007 2008 2009 2019 2020 2021 2017 2012 2010 2011 2014 2015 2016 2018 Continued execution of biopharma strategy 6 New product portfolio launches LOE LOE LOE LOE acquisition divestiture Portfolio transformation enabled by strong track record of commercial execution

From 11 to 22 Phase 3 & registrational expansion opportunities Deepening our innovation engine since 2019 7 Deeper pipeline Expanded research platforms Industry leading Protein Homeostasis capability Expanding Cell Therapy platforms Broader external partnership network Currently >300 From 29 to 64 Phase 1 & 2 assets

Well positioned with a diverse portfolio of leading medicines 8 Leading Products across Four Therapeutic Areas Robust Early-stage Pipeline** Across leading drug discovery platforms:Small moleculesProtein homeostasisBiologicsCell therapy **Phase I / II Assets Financial strength enabling continued investment for growth Solid Tumor Oncology deucravacitinib* mavacamten* + Expansion opportunities across multiple assets 50+ assets Hematology Cardiovascular Immunology Deep & Broad Late-stage Pipeline New Product Portfolio rela+nivo FDC* milvexian BCMA TCE cendakimab bempeg iberdomide FRa ADC CC-92480 * Anticipated launches

Our Commitment as a sustainable organization Embracing environmental stewardship 9 Experienced & diverse Board Board oversight of strategy& key enterprise risks60% female & ethnically diverse directorsShareholder rightsRegular shareholder engagementProxy access Special meeting right (15%) Environment Governance Social Key Priorities Concrete Commitments 2021 ≥ 25% new clinical trial sites in diverse metro areas 2022 Gender parity at executive level2X representation for Black/African American & Hispanic/Latino executives 2025 $1B spend with diverse suppliers 2024 Science-based emissions reduction targets established 2030 100% renewable electricity 2040 Net neutral GHG100% EV fleet100% equitable water useZero waste to landfill Maintaining highest ethics, integrity & complianceUpholding Board oversight & accountability Promoting product quality & safetyCultivating diversity, equity & inclusionEnsuring health equity, patient access & innovation

Confidence in our ability to address future key LOE exposures 10 Mid to late stage Pipeline Early-Stage Pipeline Financial strength New Product Portfolio 1H Decade Multiple drivers of growth to more than offset LOE headwinds 2H Decade $25B+ NRA revenue potential 50+ assets $45 - $50B free cash flow 2021-2023 milvexian BCMA TCE cendakimab bempeg iberdomide FRa ADC CC-92480 NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approvalFinancial projections may contain non promoted sales, BMS promotes only according to label

($12B – $14B) +$8B – $10B +$10B – $13B 2020 Revenues LOE Brands In-Line Brands Primarily I-O & Eliquis 2025 Revenues New Product Portfolio Growth 2020-2025Low to mid-single digit revenue CAGR* 2020-2025 revenue growth:Continuing Business offsets LOEs 11 LOE Brands = Revlimid, Pomalyst, Sprycel, and Abraxane Not for Product Promotional Use Continuing Business Financial projections may contain non promoted sales, BMS promotes only according to label *At constant exchange rates – Non-GAAP, on a risk-adjusted basis - There is no reliable or reasonable estimable comparable GAAP metric for this non-GAAP forward-looking information

Revlimid, Eliquis & I-O Opportunity for a more diversified portfolio in 2025 12 Not for Product Promotional Use New Product Portfolio All Other Eliquis & I-O New Product Portfolioexpected to represent ~25% of total company revenue expected in 2025, with continued growth expectedReduced concentration of top brands from ~70% in 2020 to ~50% in 2025; trend expected to continue Total Company Revenue Composition New Product Portfolio = Abecma, Breyanzi, Inrebic, Onureg, Reblozyl, Zeposia, deucravacitinib, mavacamten, rela + nivo FDC

New Product Portfolio has significant growth potential deucravacitinib $3B+ $4B+ Note: Non-risk adjusted sales subject to positive registrational trials and health authority approval $1B+ mavacamten rela+nivo FDC Broad New Product Portfolio with $25B+non-risk adjusted revenue potential in 2029 13

Solid Tumor Onc $80B+ Lung $25B+ CRC $7B+ Breast $21B+ Prostate $10B+ Ovarian $2B+ Renal $7B+ Melanoma $7B+ GI $1B+ H&N $2B+ Liver $1B+ Immunology $75B+ RA $28B+ Psoriasis $20B+ PsA $4B+ Ank. Spond. $1B+ Lupus $1B+ Atopic Derm $4B+ UC $6B+ Crohn’s $13B+ Hematology $40B+ MM $20B+ NHL $11B+ MDS $1B+ AML $1B+ CLL $6B+ Broad pipeline addresses diseases with significant commercial potential Mid to late-stage pipeline Early-stage pipeline milvexian BCMA TCE cendakimab bempeg iberdomide FRa ADC CC-92480 50+ assets Focused in disease areas with large and growing commercial potential Cardiovascular $20B+ HF $3B+ Thrombosis $19B+ Source: EvaluatePharma 2020 estimates 14

Current focus: Emerging science-based in-licensing opportunitiesSmall & mid-sized bolt-on opportunities to strengthen innovation engine & long-term growth profile Consistent criteria for sourcing external innovation Business Development remains a top priority 15 Strategically AlignedScientifically SoundFinancially Attractive Not for Product Promotional Use OncologyHematologyImmunology Focusedon therapeutic areas of interest CardiovascularNeurology

New Product Portfolio and pipeline provide multiple pathways to growth from 2025 to 2029 New product portfolio and pipeline products will continue to provide revenue replacement power, offsetting Eliquis and I-O LOEs Additional optionality from disciplined Business Development Delivery of late-stage pipelineCombination of new products & high-value expansion opportunities:Reblozyl LCMdeucravacitinib LCMmavacamten LCMrelatlimab LCMmilvexianiberdomide 2025 Revenues LOE Brands 2029 Revenues Additional growth from New Product Portfolio Advancing robust pipeline Diverse, growing New Product Portfolio Growth 2025-2029 16

Critical 2022 & 2023 deliverables to unlock value of New Product Portfolio Enable expansion forReblozyl through successful1L MDS COMMANDS trial 17 deucravacitinib mavacamten Deliver successful launch of mavacamten over the next year Establish deucravacitinib as oralof choice in Psoriasis Establish broad access for Zeposia in UC Build industry-leading cell therapy franchise, anchored on Breyanzi

What we will cover with you today 18 Provide insight to our innovation engine Rupert Vessey Samit Hirawat Chris Boerner David Elkins Review ourmid & late-stage pipeline Discuss the building blocks of growth Review our financial strength & approach to capital allocation

Innovation Engine & Early Pipeline Rupert Vessey,MA, BM, BCh, FRCP, DPhil President, Research & Early Development

R&D Strategic Foundation An innovation company developing first-in-class & best-in-class medicines addressing significant unmet need 20 External Partnerships Portfolio Execution Talent Key Enablers of Our Success Innovative R&D Platforms Digital Innovation

An Integrated Approach to Research and Development 21 Global Drug DevelopmentMaximize innovation and productivity for late stage and LCM opportunities Research & Early DevelopmentDrive innovation and bring forward next generation assets

Differentiated and Diversified Portfolio Grown through Internal R&D and BD 22 Distribution of clinical pipeline (2019 to 2021) # of assets Diversifying portfolio across TAs Rich early and mid-stage pipeline Modality agnostic approach 5 2019 40 2021 4 3 86 Neuroscience Cardiovascular Hematology Fibrosis Immunology Oncology 86 11 2021 2019 Ph1, Ph2 Ph3, LCM 86 40 2021 2019 Biologic Small Molecule Cell Therapy 4 40

Industry Leading Drug Discovery Platforms 23 Complex Biotherapeutics Small Molecule Drug Discovery Protein Homeostasis Cell Therapy Screening2.5MM Cmpds50K CelMods Hit ValidationExploratory SAR CryoEM Lead OptimizationMedchem - RadiochemML - Cheminformatics New Targets Drug Candidates Cro Network CAR T technology: recognizes proteinson the surface of cancer cells TCR technology: recognizes intracellular tumor-specific proteins CAR TCR Probodies Immune Cell Engagers Bi-Specifics Site Specifics ADCs

Novel Assets Advancing from our Protein Homeostasis Platform 24 CELMoD LDD Novel Target Cereblon Target Ligase Target ? Molecular Glue Heterobifunctional Intrinsic Degrader 1 2 3 Modalities Asset Indication Phase iberdomideA/I* CELMoD MM Late Development CC-92480A/I* CELMoD MM Late Development CC-90009GSPT1 CELMoD AML Early Development CC-99282A/I* CELMoD Lymphoma Early Development CK1α CELMoD AML Early Development AR-LDD Prostate Cancer Early Development 2 Novel LDD5 Novel CELMoD Heme-Onc, Inflammation Full Discovery * Aiolos/Ikaros

Broad Investment in Next Generation Cell Therapies 25 Engineered TCR T Cells for Solid Tumors CAR T Armed Payload Recognizes intracellular targets Overcoming tumor microenvironment resistance Healthy donors Patients Allogeneic CAR T Cells Off the shelf alternative Enabled through strategic partnering Dual Antigen Targeting CAR Ts Mitigating antigen loss

Immune Cell Engager Molecules are Complementary Modalities to Cellular Therapy 26 Current Portfolio (public) Bispecific Antibodies: Direct host immune cells (T or NK) to recognize & attack tumor cells Indication Asset Disc Pre-clinical Ph1 AML CD33 NKE AML target NKE AML target NKE Lymphoma / CLL BCM target NKE BCMA TCE Myeloma BCMA NKE BCMA TCE Solid Tumor Solid tumor target TCE ST target NKE ST target NKE Inflammation/neuroscience NS target NKE (CC-93269)

>85Active Collaborations 4INDs Filed 2021 9Licenses Optioned 2021 Internal R&ED Strengths are Amplified through Active External Partnerships 27 Neuroscience Immuno- Oncology & Cell Therapy Oncogenesis Tumor Micro- Environment Mechanisms of Cancer Resistance Cross-Therapeutic Informatics & Predictive Sciences Discovery Biothera-peutics Small Molecule Drug Discovery Inflammation, CV & Fibrosis EXEMPLAR MMPACT

Rapidly Advancing Neuroscience Pipeline Built through External Partner Network 28 By end of 2023, five assets will have completed Phase 1 and two assets will have Phase 1 ongoing Machine learning Protein Homeostasis Protein Clearance RNA Splicing Remyelination and Repair Neuroinflammation Zeposia approved US and EU 2020 Mitophagy Endocannabinoid enhancer IND 2020: FIH June 2020 CC-97489 Multiple SclerosisNeuroinflammation

Opportunities for Visibility and Guidance Increasing Optionality for Additional Platforms and Technologies via Strategic Equity Investments Potential 1st mover advantage for early data access and partnership opportunitiesBoard observer seats provide opportunities to provide guidance on research and development 29 Equity Portfolio Focus Direct Equity LP Venture Capital Actively Managed Incubators Description Direct relationships with innovative companies seen as too early stage or inaccessible for broader partnership~ 75 investments Deliberately constructed VC portfolio to provide access to innovation across geographies, company stages, TAs and sectors Partnerships between incubators and BMS support innovation arising from academic centers across multiple geographies Examples Pure direct equity: Orna, AktisEquity structured with partnership: Arsenal Bio Company creation: Avalon BioventuresDedicated focus: Droia Genetic Medicines Fund Geographic diversity: LAB2030Incubator to Accelerator: Dark Blue Therapeutics ~$5B total equity investments

Integrating AI & Machine Learning into Drug Discovery and Development to Enable Better Decisions and Faster Execution 30 Compound OptimizationReduced cycle times |Computer assisted design Phenotypic ScreeningNovel targets | CELMoD ® MoA Biomarker DiscoveryMulti-omics analysis | Digital pathology | Imaging Protocol Design Competitive positioning | Virtual trial augmentation | Novel endpoints Hypothesis ValidationLarge internal datasets | Signal detection| Patient selection Trial ExecutionPatient data collection| Improved Site/Investigator Communication CTDI Discovery through Proof-of-concept Registrational Program Execution

BCMA TCE GSPT1 CELMoD(CC-90009) Phase 1 POC / initiation of registrational development Hematology Fibrosis Immunology Oncology Cardiovascular Neuroscience Phase 1 / Phase 2 Pipeline Anti-SIRPα1(CC-95251) BCMA CAR T(bb21217) BET Inhibitor1(CC-90010) BET Inhibitor (CC-95775) FXIa Inhibitor S1PR1 Modulator TYK2 Inhibitor Anti-TIGIT Anti-TIM3 CD3xPSCA2(GEM3PSCA) STING Agonist Anti-Fucosyl GM1 Anti-NKG2A3 motolimod BCMA ADC milvexian(FXIa Inhibitor) Opportunity for >20 POC decisions in the next three years CD19 NEX T3 BCMA NEX T3 Anti-CTLA-4 NF PB Anti-OX40 FAAH/MGLLDual Inhibitor AR LDD3 FPR-2 Agonist CD47xCD203 GPRC5D CAR T3 CD33 NKE3 Anti-CD403 IL2-CD253 LSD1 Inhibitor1 TGFβ Inhibitor MK2 Inhibitor HSP47 branebrutinib Imm. Tolerance (Anokion)2 A/I CELMoD (BCM)(CC-99282) Anti-CTLA-4 NF BET Inhibitor(BMS-986158) Anti-IL-8(BMS-986253) Anti-CTLA-4 PB LPA1 Antagonist FA-Relaxin afimetoran(TLR7/8 Inhibitor) danicamtiv Cardiac Myosin Inh.(MYK-224) Phase 1b/2 Hematology Oncology Immunology CV Fibrosis Neuroscience Legend IL-12 Fc(BMS-986415) Anti-CCR83 TIGIT Bispecific CK1α CELMoD3 BCMA NKE3 ROR1 CAR-T3 Anti-Tau2,3(PRX005) BTK Inhibitor3 eIF2B Activator3 AHR Antagonist2(IK-175) NME ROMK Inhibitor 1 In development for solid tumors and hematology2 BMS has an exclusive option to license and/or option to acquire3 IND/CTA approved iberdomide A/I CELMoD (MM)(CC-92480) farletuzumab - eribulin ADC 31

CC-99282, a novel CELMoD Ikaros/Aiolos degrader optimized for NHL CC-99282 designed for rapid and maximal substrate degradation profileDemonstrates broad and potent cell autonomous activity (cell death) in DLBCL cell linesSignificant in vivo activity in both ABC and GCB DLBCL xenografts, with regression and tumor free mice on either QD or intermittent schedulesDistribution profile that favors target tissues (lymphoid organs) Lopez-Girona, A. et al. CC-99282 is a novel cereblon E3 ligase modulator (CELMoD) agent with potent and broad antitumor activity in preclinical models of diffuse large B-cell lymphoma Hematol Oncol. 2021 Protein Homeostasis 32

CC-99282-NHL-001a: study design and objective 33 aStudy number NCT03930953; CAR, chimeric antigen receptor; FL, follicular lymphoma; MTD, maximum tolerated dose; PK, pharmacokinetics; RP2D, recommended phase 2 dose; R/R, relapsed or refractory. Key eligibility criteria (Part A)R/R DLBCL or FL≥ 2 prior regimens including CELMoD agent or CAR T cell therapyOR R/R DLBCL≥ 1 prior regimen and ineligible for transplant Study endpointsPrimary: safety, tolerability, MTD, RP2DSecondary: PK, preliminary efficacy of CC-99282 monotherapy Part A: dose escalation Part B: dose expansion Objective: To evaluate safety and preliminary efficacy of CC-99282 in R/R DLBCL and FL Michot J-M, et al. ASH 2021. Abstract #3574 3 distinct intermittent dosing schedules:≥ 3 patients per dosing cohort RP2D 0.4 mg 0.2 mg … 0.2 mg Cohort AR/R DLBCL: CC-99282 Cohort BR/R FL: CC-99282 Cohort CR/R DBLCL: CC-99282 + rituximab Cohort DR/R FL: CC-99282 + rituximab Protein Homeostasis

CC-99282: Encouraging Early Profile in NHL Patient baseline characteristic Overall (n = 35) Age, median (range), years 66.0 (35–81) DLBCL, n (%)FL, n (%) 30 (85.7)5 (14.3) No. of prior anticancer tx, median (range) 3 (1–8) Failure of last anticancer tx, n (%) 20 (57.1) Stem cell transplant, n (%) 7 (20.0) CAR T cell therapy, n (%) 7 (20.0) Safety Overall (n = 35) ≥1 Gr3/4 TEAEs related to CC-99282, n (%) 21 (60.0) Hematologic TEAEsNeutropeniaFebrile neutropeniaThrombocytopenia 19 (54.3)2 (5.7)3 (8.6) Nonhematologic TEAEsDiarrheaFatigue 1 (2.9)1 (2.9) CC-99282 monotherapy showed a predictable and manageable safety profile and demonstrated promising efficacy in heavily pretreated pts with R/R NHL with PK/PD data consistent with robust CC-99282-mediated antitumor activity. Data cut: 09Apr2021; Michot, JM. et al. Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator(CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/RNHL) – First Results from a Phase 1, Open-Label StudyTo be presented at ASH 2021. Abstract #3574 Best overall responses * Includes patients who received ≥ 0.4 mg on tolerated dosing schedules CR, complete response; ORR, overall response rate; PR, partial response Interim PK/PD analyses showed that increase in plasma CC-99282 and degradation of Ikaros/Aiolos in peripheral T cells occurred in a dose-dependent manner where maximum degradation (> 90%) occurred by day 4 of treatment at doses ≥ 0.4 mg 34 Protein Homeostasis

CC-95251: A Novel anti-SIRP-alpha Monoclonal Antibody ADCP, antibody-dependent cellular phagocytosis; FcγR, Fc gamma receptor; NHL, non-Hodgkin lymphoma; SIRPα, signal regulatory protein alpha. Abstract 2493: Interim results from the first clinical study of CC-95251, an anti-signal regulatory protein alpha (SIRPα) antibody, in combination with rituximab in patients with relapsed and/or refractory non-Hodgkin lymphoma (R/R NHL)Paolo Strati,1 Eliza Hawkes,2 Nilanjan Ghosh,3 Joseph Tuscano,4 Quincy Chu,5 Mary Ann Anderson,6 Amar Patel,7 Michael R. Burgess,7 Kristen Hege,7 Sapna Chhagan,7 Sarandeep Boyanapalli,7 Tracey Day,7 Frank Shen,7 Amitkumar Mehta81The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Austin Health-Austin Hospital, Heidelberg, VIC, Australia; 3Levine Cancer Institute, Charlotte, NC, USA; 4University of California, Davis, Sacramento, CA, USA; 5Cross Cancer Institute, Edmonton, AB, Canada; 6Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 7Bristol Myers Squibb, Princeton, NJ, USA; 8University of Alabama at Birmingham, Birmingham, AL, USA NHL cancer cell CD47 CC-95251 Antitumor immunity FcγR Rituximab SIRPα FcγR CD20 SIRPα Reduced negative regulation of phagocytic cells Increased ADCP Potential for enhanced adaptive immune response via increased antigen presentation Macrophage Phagocytosis + Zhang W; et al. Front Immunol 2020;11:18; Sockolosky JT, et al. PNAS 2016;113(19):E2646-54. 35 Biotherapeutic

CC-95251: Phase 1 study design and dose schedule Dose escalation Dose expansion aAdministered intravenously. b375 mg/m2; cAdministered at/below the MTD. Key eligibility criteriaInclusion criteria:CD20+ R/R NHLECOG PS 0–1Disease progression on standard anticancer therapy or no approved conventional therapy availablePrior SCT and CAR T cell therapy permittedExclusion criteria:No prior CD47/SIRPα investigational therapyNo chronic systemic immunosuppressive therapy Part A objectivesTo determine MTD/RP2DTo assess safety CC-95251c + rituximabin DLBCL CC-95251 3 mg/kg + rituximabn = 3 CC-95251 10 mg/kg + rituximabn = 7 CC-95251 20 mg/kg + rituximabn = 7 CC-95251c + rituximabin FL Rituximaba,b C6-24: D1 of every other cycle Abstract 2493: Interim results from the first clinical study of CC-95251, an anti-signal regulatory protein alpha (SIRPα) antibody, in combination with rituximab in patients with relapsed and/or refractory non-Hodgkin lymphoma (R/R NHL)Paolo Strati, et. al. ASH 2021. C1 C2 C3 C4 C5 C6 C7 C8 C1: D1, 8, 15, 22 CC-95251 QWa C2-5: D1 All 28-day cycles CAR, chimeric antigen receptor; DLBCL, diffuse large B-call lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; MTD, maximum tolerated dose; NTD, non-tolerated dose; PK, pharmacokinetics; QW, weekly; RP2D, recommended phase 2 dose; SCT, stem cell transplant. 36 Biotherapeutic

CC-95251: Encouraging Early Profile in NHL aRelated to CC-95251; bSafety population; cIncluding a grade 5 septic shock not related to treatment; dEfficacy-evaluable population.AST, aspartate aminotransferase; CR, complete response; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; ORR, overall response rate; PR, partial response; TEAE, treatment-emergent adverse event. Best overall response Strati P, et al. Interim results from the first clinical study of CC-95251, an anti-signal regulatory protein alpha (SIRPα) antibody, in combination with rituximab in patients with relapsed and/or refractory non-Hodgkin lymphoma (R/R NHL) ; To be presented at ASH 2021. Abstract 2493. Baseline patient characteristics All patients(N = 18) Age, median (range), years 69 (30–84) Tumor types, n (%) DLBCL 14 (78) FL 2 (11) MCL 1 (6) MZL 1 (6) Prior systemic therapies, median (range) 4 (1–7) Common TEAEs (> 20 % all grade) All-cause Treatment-relateda Any graden = 17b Grade ≥ 3n = 17b Any graden = 17b Grade ≥ 3n = 17b Hematologic TEAEs, n (%) Neutropenia 11 (64.7) 9 (52.9) 9 (52.9) 8 (47.1) Thrombocytopenia 4 (23.5) 1 (5.9) 3 (17.6) 0 Non-hematologic TEAEs, n (%) Infection 9 (52.9) 4 (23.5)c 3 (17.6) 1 (5.9) Hypokalemia 6 (35.3) 0 0 0 Hypomagnesemia 6 (35.3) 0 1 (5.9) 0 Fatigue 5 (29.4) 0 3 (17.6) 0 Headache 5 (29.4) 0 2 (11.8) 0 Infusion-related reaction 5 (29.4) 0 2 (11.8) 0 Nausea 5 (29.4) 0 1 (5.9) 0 AST elevation 4 (23.5) 0 4 (23.5) 0 Hypophosphatemia 4 (23.5) 0 1 (5.9) 0 Increased creatinine 4 (23.5) 0 0 0 37 Biotherapeutic

Pleiotropic effects on innate and adaptive immune cells within the TMEStriking antitumor activity in a variety of preclinical models (monotherapy and in combination) Monovalent IL-12 Fc fusion protein Extended half-life prolonged IFNg PD response, broadening therapeutic indexFirst-in-class opportunity Narrow therapeutic index with systemically delivered IL-12 BMS-986415: Novel IL-12 Fc Linking Innate and Adaptive Immunity in the Tumor Microenvironment 38 August 2020: Exclusive Global License for Dragonfly's IL-12 Investigational Immunotherapy Interleukin-12 (IL-12) Solution: BMS-986415 Therapeutic Challenge BMS-986415 (IL-12 Fc) – Phase IA Biotherapeutic

CT26: Large Tumors Preclinical mouse surrogate molecule shows extended PK prolongs PD and provides single agent efficacy 39 Prolonged and Moderate (Peripheral) IFN response mDF6006 (1 µg single dose) CT26: Checkpoint-nonresponsive Model mDF6006 (mouse surrogate of BMS-986415, 1 µg weekly IP or SQ)Tumor volumes are mean values with SEM. *P = 0.0002, **P < 0.0001 with 2-way analysis of variance.aCT26-20.7 subline expressing Tyrp1 tumor-associated antigen; bTwo mice were removed from the isotype group (1 on day 15 and 1 on day 19) due to tumor rupture; cOne mouse was removed on day 19 due to tumor rupture; dOne mouse was removed on day 27 due to tumor rupture. Preclinical Highlights Gutierrez, E. et al. Cancer Res July 1 2021 81 (13 Supplement) 1714 Poster presentation at the American Association for Cancer Research Annual Meeting; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA, USA. Biotherapeutic

Study progress: Dose escalation ongoing, no dose limiting toxicities to date Mono escalation: Enrolling BMS-986415: Study status and updates 40 Combination escalation with nivolumab: Enrolling Biotherapeutic

Biological Rationale for Targeting the IL-8 Pathway Primary Hypothesis (Role of IL-8 in Immunosuppressive Tumor Microenvironment):IL-8 blockade will relieve immune suppression induced by PMN-MDSC to enhanced anti-tumor immunity in combination with nivolumab 41 Bakouny, Z., Choueiri, T.K. IL-8 and cancer prognosis on immunotherapy Nat Med 26, 650–651 (2020). Biotherapeutic

Role of IL-8 in Mediating I-O Resistance was Validated using Phase 3 Checkpoint Inhibitor Clinical Trials 42 Schalper KA et al. Nat Med 2020;26:688-692 IL-8 promotes the trafficking of immunosuppressive PMN-MDSCs into TME (CM-017, CM-057) Reduced OS in CPI Treated Patients with elevated Serum IL-8 (CM-067) Similar findings in patients with lung, RCC and bladder cancer (NSCLC CM-017/057], RCC CM-025, bladder IMVIGOR-210/211)* Biotherapeutic

BMS-986253: A Novel Anti-IL-8 Monoclonal Antibody shows Preliminary Clinical Activity with Nivo in Melanoma 43 Durable stable disease and partial responses were observed in patients with melanomaPartial responses were observed in 5 of 28 patients with melanoma; all 5 patients with partial response had received prior anti–PD-(L)1, and 4 of the 5 patients had also been previously treated with anti–CTLA-4 100 50 -50 0 0 10 20 30 40 Weeks Melanoma (n = 28) Change from baseline in tumor burden (%) 50 60 70 80 Response Progressive disease Stable disease Partial response Treatment ongoing First occurrence of PR/CR First occurrence of PD New lesion c c c c b -100 aPer RECIST v1.1. Response-evaluable patients, defined as all treated patients with measurable disease at baseline and ≥ 1 postbaseline tumor assessment, clinical progression, or death. 27 of 28 evaluable patients with melanoma had received prior anti–PD-(L)1; 23 of the 28 patients also had prior anti–CTLA-4; bPrior therapy included anti–PD-(L)1; cPrior therapies included anti–PD-(L)1 and anti–CTLA-4. Davar D et al. Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results. Presented at the SITC 2020 Annual Virtual Meeting; November 9–14, 2020 Biotherapeutic

BMS-986253:Pursuing Formal Proof of Concept in a Randomized Ph2 in Post-PD(L)1-Treated Melanoma Patients 44 Arm A: nivo/ipi/anti-IL-8 Randomize All Comers(1:1) Arm B: nivo/ipi Stratify by serum IL-8, BRAF and LDH Patient Population:Unresectable or Metastatic Melanoma, with progression on PD(L)1 inhibitorPD(L)1 as most recent prior therapyCTLA-4 Naïve Primary Comparison:PFS in sIL-8+ patients Secondary Comparison:PFS in All-Comers Other Endpoints:ORR, OS Key Study Design ElementsEstablish efficacy in refractory melanoma patients following treatment with anti-PD(L)1 inhibitorsRobust POC study design that confirms contribution of anti-IL-8 therapy to nivo/ipi combination Validation of patient enrichment strategy by conducting primary analysis in sIL-8 positiveStudy design that exhibits probability of regulatory and technical success NCT03400332: https://clinicaltrials.gov/ct2/show/NCT03400332 Biotherapeutic

Innovation Engine provides significant opportunity for pipeline sustainability Rich and deep pipeline across modalities and therapeutic areasIndustry leading internal discovery platforms across small molecules, complex biologics, protein homeostasis, and cell therapyStrong complementary external network to source emerging innovationPipeline and platform delivering tangible results including within protein homeostasis and biologics 45

Samit HirawatChief Medical Officer,Global Drug Development Late-Stage Pipeline Update

Significant progress advancing the pipeline Cardiovascular - Oncology - Hematology - Immunology AHAmilvexianmavacamten ASHBreyanziCELMoDs Furthering development of expansion opportunities Advancing science across all key therapeutic areas Important new data at recent conferences EADVdeucravacitinib 47

Opportunity to extend our leadership in anti-thrombotics Successful history of developing leading CV medicines Expand into cardiomyopathies Opportunity for sustained leadership in Cardiovascular 48 mavacamten milvexian Cardiovascular

Substantial unmet need persists in thrombotic diseases Bleeding risk currently limits usage 49 Significant opportunity for an agent with comparable or better efficacy & reduced bleeding risk over Factor Xa inhibitors Patients with high bleed risk also at higher thromboembolic risk Concerns today with combining OACs & dual-antiplatelet therapy Opportunity to enhance benefit/risk Room to advance carebeyond substantial advances of FXa Many patients remain untreated or undertreated (with respect to anticoagulation) due to bleeding risk Cardiovascular

MOA supports opportunity to improve benefit/risk profile with an oral FXIa inhibitor 50 Extrinsic Pathway Intrinsic Pathway Tissue Factor FVIIa FVII Vesselinjury Common Pathway FXII FXIIa FIX FIXa FX FXa FII FIIa/Thrombin FXI FXIa Thrombin Feedback apixaban milvexian Cardiovascular

Milvexian Phase 2 trials will inform optimal dose/regimen for Phase 3 program Positive trialFull data presented at AHA 2021 & in NEJM* Secondary Stroke Prevention (SSP) Study Milvexian + clopidogrel + aspirin vs placebo + clopidogrel + aspirin in patients with acute ischemic stroke or transient ischemic attack(N=2350) Total Knee Replacement (TKR) StudyMilvexian vs enoxaparin in patientsundergoing elective total knee replacement surgery(N=1242) Readout expected 1H 2022 51 Cardiovascular *published November 15, 2021 at https://www.nejm.org/doi/full/10.1056/NEJMoa2113194?query=featured_home

Milvexian Phase 2 TKR trial design Milvexian vs enoxaparin*Open-label multicenter, dose-ranging study 25 mg to 400 mg total daily dose10 to 14 day exposureStudy objectives:To demonstrate effectiveness in preventing total VTE events during treatment periodTo assess the dose response of milvexian for the occurrence of bleeding events 52 1242subjects R milvexian 25 mg BID(153) milvexian 50 mg BID(150) milvexian 100 mg BID(152) milvexian 200 mg BID (153) Open-Label enoxaparin SC 40 mg QD(301) milvexian 50 mg QD†(150) milvexian 200 mg QD(149) milvexian 25 mg QD †(34) *enoxaparin @ 40-mg daily dose† Milvexian 25 mg QD stopped by Operations committee, replaced by milvexian 50 mg QD Cardiovascular

Profile of milvexian is differentiated from existing anti-thrombotics 53 N*: based on efficacy (ITT) data set enoxaparin, mg milvexian, mg N* 40 mg QD (n=252) 25 mg QD (n=28) 50 mg QD(n = 127) 25 mg BID(n = 129) 50 mg BID(N = 124) 200 mg QD (n=123) 100 mg BID (n=134) 200 mg BID (n=131) All VTE + all death 21.4 25.0 23.6 20.9 11.3 6.5 9.0 7.6 All Bleeding, % 4.1 0 5.3 1.4 4.7 6.1 4.7 3.4 Major or CRNM Bleeds 1.7 0 1.3 0 1.4 0.7 0.7 0.7 - Major 0.3 0 0 0 0 0 0 0 - CRNM 1.4 0 1.3 0 1.4 0.7 0.7 0.7 - Minor 2.7 0 4.0 1.4 3.4 5.4 4.7 2.7 Robust efficacy with clear dose-response Low risk of bleeding No major bleeds observed in milvexian arms No dose response in bleeding observed in doses ≥50 mg -> distinct from existing anticoagulants Note: CRNM bleeds = clinically relevant non-major bleeds Cardiovascular

Scientific community recognizes important data for Milvexian, potential next generation anti-thrombotic 54 Cardiovascular

Milvexian Phase 2 SSP trial design 55 Topline data expected 1H 2022 Study objectives:Provide data on top of dual anti-platelet therapyAssess longer exposure — up to 90 day treatmentFurther insight into efficacy and bleeding profile \ 2350subjects R Arm A – placebo + 100 mg aspirin + 75 mg clopidogrel Arm B – milvexian 200 mg BID + 100 mg aspirin + 75 mg clopidogrel Arm C – milvexian 100 mg BID + 100 mg aspirin + 75 mg clopidogrel Arm D – milvexian 50 mg BID + 100 mg aspirin + 75 mg clopidogrel Arm F – milvexian 25 mg QD + 100 mg aspirin + 75 mg clopidogrel Arm E milvexian 25 mg BID + 100 mg aspirin + 75 mg clopidogrel Cardiovascular

Multiple potential opportunities for novel antithrombotic Anti-platelets1SSPACSCAD/PAD Factor Xa1VTEAFIB Potential universe of indications Milvexian Optionality for Ph3 program pending SSP Ph2 results SSP = secondary stroke prevention; ACS = acute coronary syndrome; CAD = coronary artery disease; PAD = peripheral artery disease; VTE = venous thromboembolism (prevention and/or treatment-related indications); AFIB = atrial fibrillation 1Represents indications with majority of usage 56 Cardiovascular

Opportunity to improve outcomes for patients on existing treatments Milvexian: significant opportunity for next generation anti-thrombotic Ph3 program expected to begin as early as 2H 2022 57 Similar or better efficacyBetter bleeding profile Clear benefit over enoxaparin No major bleeds observed; no dose response in bleeding ≥50mg BID Expected to further define the profile TKR Phase 2 data demonstrate differentiated anti-thrombotic profile SSP data expected 1H 2022 Registrational program planningin progress Cardiovascular

Hypertrophic cardiomyopathy (HCM) disease profile Significant unmet need for symptomatic HCM Thickening of the heart muscle due to:hypercontractility — impaired relaxation — hypertrophyAffects 1 in 500 people; most common genetic heart disease Symptoms include: palpitation, dizziness, breathlessness, tiredness, chest pain, sudden cardiac arrest 58 Hypertrophic Heart LVOT1 obstructionDecreased left ventricular volumeThickened heart muscle and septum Normal Heart 1. LVOT = Left ventricular outflow tractSource: Olivotto. Lancet. 2020; Maron. NEJM. 2018; Marian. Circ Res. 2017; Maron. J Am Coll Cardiol. 2016; Veselka. Lancet. 2016; Maron. J Am Coll Cardiol. 2015; Ahmad. Annu Rev Genomic Hum Genet. 2005; Maron. JAMA. 1999; Maron. Circulation. 1995. Currently no approved medicines that address underlying disease Diagnosed by echo-cardiogram Typical age of diagnosis in the ~40s-50s Subset of patients have severe symptoms Current therapeutic options limited to symptom-treating generic drugs (e.g., beta-blockers) Cardiovascular

Mavacamten: a potential first-in-class medicine that addresses underlying disease in oHCM Marked improvements in cardiac function & symptoms: 65% pts improved by ≥ 1 NYHA class (vs 31% with placebo)Clinically meaningful reduction in LVOT gradients; sustained reduction in key cardiac biomarkers Positive impact on health statusWell tolerated safety profile 59 PDUFA: Jan 28, 2022 ESC 2020: Positive Ph3 results from EXPLORER-HCM ACC 2021: Long-term data from the EXPLORER cohort ofMAVA-LTE show durability of improvement & confirm safety profile NYHA = New York Heart Association Cardiovascular Olivotto, et al, Lancet 2020Rader, et al, J Am Coll Cardiol, 2021 May, Supplement

Expanding the oHCM label with VALOR-HCM 60 Primary EndpointComposite ofdecision to proceed with SRT prior to or at wk 16+ SRT guideline eligible at wk 16, but declined VALOR-HCM Study Design Patients with symptomatic oHCM, eligible for SRT*N=100 (US only) 1:1 Randomization mavacamten2.5,5,10,15 mg QD placebo (thru wk 16) Treatment phase 32 wks Long-term extension to wk 136 Potentially registrational trialDemonstrate mavacamten’s potential in high-risk patients and prevent the need/eligibility for highly invasive SRTData expected in 2022 * Septal reduction therapy mavacamten 2.5,5,10,15 mg QD Cardiovascular Desai, et al, Am Heart J, Sep 2021

AHA 2021 (abstract #9685)Long term data demonstrate:Sustained NT-proBNP reductionImprovement in cardiac fill & function, as measured by E/e’ & LAVI No new safety signals Median (IQR) NT-proBNP over time in the total population (N = 43) Data from MAVERICK, & MAVERICK cohort of MAVA-LTE support Ph3 initiation in nHCM in 2022 Improvement in myocardial wall stress, as measured by NT-proBNP cardiac biomarkerWell tolerated safety profile 61 ACC 2020: Positive Ph2 results from MAVERICK-HCM Note: E/e’ is an echocardiographic measure of filling pressures in the heart; LAVI = left ventricular volume index Cardiovascular Ho, et al, J Am Coll Cardiol, Jun 2020

Mavacamten indications and pipeline opportunities 62 P1 P2 P3 Mavacamten has potential to make a significant impact in the CV space, starting with oHCM EXPLORER-HCM oHCM NYHA ClassII & III completed oHCM potential SRT alternative VALOR-HCM MAVERICK-HCM and MAVA-LTE nHCM EMBARK-HFpEF Precision diastolic disease (HFpEF) oHCM PDUFA: January 28, 2022 Topline data expected in 2022 Ph2 MAVERICK & MAVA-LTE data informing plans to initiate Ph 3 in 2022 Ph2 POC initiated Cardiovascular

Advance broad early pipeline Leverage leading expertise in hematology Expand key new medicines Opportunity to advance leadership in Hematology 63 Hematology

CC-92480CC-92480+bort+dex in 4L+ MM patients (presentation #2731)Differentiated potency supported by encouraging clinical combination data Upcoming ASH data support important progress advancing hematology pipeline 1st cell therapy to demonstrate benefit over SOC 2L LBCL data (TRANSFORM) (presentation #91) 64 Encouraging new data on early pipeline assetsGPRC5D CAR T (MSKCC abstract #153204)CC-99282 (presentation #3574) & SIRPα (presentation #2493) IberdomideIber+dex in 4L+ MM patients (presentation #162)Profile supports advancing therapy in earlier lines Hematology

Breyanzi TRANSFORM data: demonstrates further potential of Cell Therapy treatments 65 Supports Breyanzi as potential new SOC for 2L treatment in R/R LBCL mEFS = 10.1 (95% CI, 6.1–NR); HR=0.349;P < 0.0001 Primary endpoint: mEFS ORR = 86% (95% CI, 77%–92.3%)P < 0.0001 Secondary endpoint: ORR First therapy to demonstrate benefit vs. SOCStatistically significant & clinically meaningful improvement in primary & and key secondary endpointsNo new safety concerns: CRS all grades: 49% CRS Gr3:< 1%NE all grades: 12% NE Gr3: 4% Data from ASH abstract Hematology

Continuing to expand Breyanzi Best-in-class CD19*Strong efficacy demonstrated in 2L and 3L+ LBCLDifferentiated side effect profile, incl. low rates of CRS & NE 66 Registrational program & data availability TRANSFORM 2L TE (Breyanzi vs SOC) TRANSCEND-CLL-004 Phase I Phase II Pivotal PILOT 2L TNE (single arm) TRANSCEND FL 3L+ ASH 2021 LBCL iNHL (FL & MZL) 3L+ CLL 2022 2023 2021 2L+ CLL Study planned Hematology *lower rates of Gr3/4 CRS and NE

CELMoDs could replace the current foundation of care 67 1L 2L 3L 4L Revlimid today Pomalyst today Replace Revlimid as foundation of frontline multiple myeloma treatment Iberdomide vision Replace Pomalyst as foundation of treatment in relapsed refractory multiple myeloma (RRMM) CC-92480 vision Success Factors Demonstrate superiority to IMiD agents (Revlimid, Pomalyst)Combine CELMoDs broadly with existing SoCEstablish proprietary novel combinations to displace SoCDevelop multiple assets to enable sequential treatment Data to be presented at ASH support strategy Hematology

Iberdomide: CC-220-MM-001: Phase 1b/2a study design 68 RRMM, prior len or pomPrior proteasome inhibitorDocumented PD during or within 60 days of last anti-myeloma therapy Cohort D:iber (1.6mg qd, RP2D) + dex Cohort E: iber + dara + dex(iber: 1.0mg qd-1.6mg qd) Study endpoints:Primary: to determine MTD/RP2D and efficacy Secondary: to assess safety Phase 1: Dose Escalation Phase 2: Dose Expansion Cohort C: iber (RP2D) Data at ASH 2021 Cohort B: iber + dex(iber: 0.3mg to 1.6mg qd) Cohort A: iber (iber: 0.3mg qd-1.0mg qd) Cohort F: iber + bort + dex(iber: 1.0mg qd-1.6mg qd) Cohort G: iber + cfz + dex(iber: 1.1mg qd) Refractory to 3+ prior regimens incl: Len, Pom, PI, glucocorticoid & CD38; excl. prior BCMA therapy Refractory to 3L+, post BCMA Cohort I:iber (1.6mg qd, RP2D) + dex (post-BCMA) Hematology

Note: all data shown on slide per ASH 2021 abstract; data to be presented Cohort D Grade 3-4 TEAEs: neutropenia 44.9% anemia 28% thrombocytopenia 21.5% leukopenia 20.6% GI disorders 5.6% fatigue 2.8% rash 1.9% dose interruptions due to TEAEs 52.3% dose reductions due to TEAEs 18.7% discontinuances due to TEAEs 4.7%* Iberdomide + dex: Profile to date supports advancing combination therapies into earlier lines of treatment 69 Encouraging response rates in a 4L+ population, including those pts refractory to IMiDs25% in patients who are post-BCMA treatmentFavorable tolerability profile support combination therapy; e.g., low rates of GI, fatigue, rash, discontinuations ORR 26.2% ORR 25% Manageable safety profile Cohort D Cohort I *No pts discontinued iber due to neutropenia Hematology

Iberdomide triplet combinations: Promising responses & manageable safety profile in heavily pretreated patients 70 ORRa 45.9% ORRa 56% ORRa 50.0% aPR or better; bIncludes neutropenic sepsis. Lonial S, et al. Oral presentation at EHA 2021; abstract S187 Cohort E Cohort F Cohort G Favorable safety profile Grade 3 TEAEs Cohort E Cohort F Cohort G neutropenia 66.7% 28.0% 33.3% anemia 20.5% 12.0% 0% thrombocytopenia 12.8% 24.0% 11.1% febrile neutropeniab 5.1% 0% 0% fatigue 2.6% 0% 11.1% diarrhea 2.6% 4.0% 0% rash 0% 4.0% 0% infections 15.4% 20% 33.3% Data support moving into earlier lines Increased response rates in combination with multiple standard MM therapiesFavorable tolerability maintained, e.g. fatigue, diarrhea, rash Hematology

EXCALIBER NDMM (TNE):Iber+bort+dex / iber+dara+dex, vs. RVd Iberdomide: Plans to develop as a new backbone in early line MM 71 2L+ Post transplant maintenance:Iber vs. Revlimid EXCALIBER RRMM:Iber+dara+dex vs. dara+bort+dex NDMM NDMM 2023 2023 Expected initiation timing 1H 2022 Hematology

CC-92480-MM-002: study design and objective 72 Key eligibility criteria (Cohort A)RRMM; 2–4 prior regimens including LENDisease progression during or after their last antimyeloma therapy Study endpointsPrimary: to determine MTD/RP2D and to assess safety and preliminary efficacySecondary: to evaluate additional efficacy measures Phase 1: dose escalation Cohort ACC-92480a + bort + dex Cohort BCC-92480 + dara + dex Cohort CCC-92480 + cfz + dex Cohort HCC-92480 + elo + dex Cohort ICC-92480 + isa + dex Phase 2: dose expansionb (1-3 prior lines) ClinicalTrials.gov: NCT03989414EudraCT: 2018-004767-31 Cohort DCC-92480c + bort + dex Cohort ECC-92480c + dara + dex Cohort FCC-92480c + cfz + dex Cohort JCC-92480c + elo + dex Cohort KCC-92480c + isa + dex Cohort G/NDMMCC-92480c + bort + dex a0.3, 0.6, or 1.0 mg given orally on days 1–14 of each 21-day cycle. bIf the threshold for minimum ≥ VGPR rate for Cohort D is met, an additional cohort may be opened to evaluate CC-92480 + BORT + DEX in TE NDMM patients; cAt RP2D. BORT, bortezomib; CFZ, carfilzomib; DARA, daratumumab; DEX, dexamethasone; ELO, elotuzumab; ISA, isatuximab; LEN, lenalidomide; MTD, maximum tolerated dose; NDMM, newly diagnosed multiple myeloma; RP2D, recommended phase 2 dose; TE, transplant eligible. Hematology

Differentiated potency for CC-92480 supported by encouraging clinical combination data 73 CC-92480 & dex: Scan from expansion phase Patient with EMP, extramedullary plasmacytoma The median duration of response was 10.4 (5.5–not reached) months Median time to response was 0.95 (0.7–3.3) months aPR or better; C, cycle; CBR, clinical benefit rate; CR, complete response; DCR, disease control rate; Exp, exposed; MR, minimal response; NE, not evaluable; ORR, overall response rate; PD, progressive disease; PR, partial response; Ref, refractory; reg, regimen; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response. Safety CC-92480 + bort + dex neutropenia Gr 3-4 36.9% thrombocytopenia Gr 3-4 21.1% anemia Gr 3-4 10.5% hyperglycemia Gr 3-4insomnia Gr 3-4 10.5%10.5% CC-92480 triplet combination: Strong response rates & favorable safety mainly in 4L+ ORRa 73.7% All data shown per ASH 2021 abstract; data to be presented CT at screening CT post treatment Hematology

CC-92480: Potential opportunity to replace Pomalyst for 2L+ MM patients 74 4L+ CC-92480 + dex Status: Ph2 ongoing to inform Ph3 program CC-92480+Vd vs PVd; CC-92480+Kd vs Kd 2L+ Expected to initiate registrational trials in 2023 CC-92480 + dex + bort / cfz / dara / isa / elo Ph2 ongoing to inform Ph3 program Hematology POC Registrational 2L+

Advancing our BCMA portfolio 75 1 In partnership with Dragonfly2 In partnership with Sutro3 In partnership with 2seventy bio Immune Cell Engagers Antibody Drug Conjugate T-Cell Engager CC-93269Encouraging early IV dataProgram now focused on subcutaneous formulationto maintain efficacy & reduce CRSNK-Cell Engager BMS-9863921New asset in Ph1Potential potent tumorkilling ability & less CRS ADC CC-997122Designed to avoid toxicity associated with other BCMA ADCsCurrently in dose ranging studies CAR T In market with 1st in class BCMA CAR T3 with strong demandNew wave of innovation with NEX T enables manufacturing efficiencies Hematology

Important progress advancing our Multiple Myeloma strategy 76 STRATEGIC OBJECTIVES Potential to improve upon IMiD agents and create new backbone Establish BCMA as theoptimal MM target Redefine SoC acrosslines of therapy BCMA targeting agents CELMoD agents Strategic objectives Combinations Continued innovation from early pipeline, e.g. GPRC5D CAR T Hematology

Robust Hematology Pipeline 77 Phase 1 Phase 2 Marketed iberdomide BCMA TCE CD33 NKE BCMA NKE BCMA CAR T(bb21217) ROR1 CAR T A/I CELMoD(CC-92480) CK1α CELMoD BCMA NEX T CD19 NEX T BET Inhibitor(BMS-986158) A/I CELMoD(CC-99282) GSPT1 CELMoD(CC-90009) Anti-SIRPα1 Pivotal Expansion opportunities: Reblozyl 1L MDS RebloyzlMF Breyanzi 3L+ CLL Breyanzi 3L+ iNHL Abecma 3-5L MM Breyanzi2L TE/TNE LBCL GPRC5D CAR T 1 In development for solid tumors and hematology 2 BMS has an exclusive option to license and/or option to acquire BCMA ADC CD47xCD20 BET Inhibitor1(CC-95775)

Diversify beyond I-O with differentiated platforms & novel MOAs Continue to expand Opdivo / Yervoy Extend I-O leadership through the next-generation of assets Leverage expertise to broaden & diversify in Oncology 78 Oncology rela+nivo FDC bempeg MORAb-202 ADC

Continuing to grow Opdivo / Dual I-O 1 as part of collaboration with NEKTAR 2 potential applicability in both metastatic & early stage disease Metastatic Setting Tumor/Trial Status Tumor/Trial Status 1L MelanomaCA045-001Opdivo + bempeg1 vs Opdivo 1H 2022 Readout Prostate (mCRPC)CM-7DXOpdivo + Chemo vs Placebo + chemo 2023+Readout 1L HCC CM-9DW Opdivo + Yervoy vs sorafenib / lenv. 2023+ Readout Subcutaneous nivolumab2CM-67T 2024 Readout MSI-H CRCCM-8HWOpdivo + Yervoy 2025Readout Early-Stage Setting Tumor/Trial Status Tumor/Trial Status HCC (Adj)CM-9DXOpdivo vs Placebo 2023Readout NSCLC (Adj)ANVILOpdivo vs Observation 2024Readout NSCLC (Neo-Adj)CM-816Opdivo + chemo vs chemo 2020 pCR 2023+ EFS NSCLC Stage 3 (Unresectable)CM-73LOpdivo mono, O+Y vs Imfinzi 2023+Readout Renal (Adj)CM-914Opdivo + Yervoy vs Placebo 2022 / 2023Readout (Part A) NSCLC (Peri-Adj)CM-77TNeo-adj Opdivo + chemo followed by Adj Opdivo vs chemo 2024Readout MIBC (Peri-Adj)CA017-078Opdivo + Chemo,Opdivo + IDO + chemo, vs chemo 2024Readout Melanoma (Adj)CA224-098Relatimab + Opdivo vs Opdivo 2025 Readout 22 OPDIVOapprovals 10 YERVOYapprovals 11 tumors 79 Oncology

a Per BIPR; pCR: 0% residual viable tumor cells in both primary tumor (lung) and sampled lymph nodes; b ITT principle: patients who did not undergo surgery counted as non-responders for primary analysis; c Calculated by stratified Cochran–Mantel–Haenszel method; d pCR rates 95% CI: NIVO + chemo, 18.0–31.0; chemo, 0.6–5.6 Expanding Opdivo use in early-stage lung cancer Across neo-adjuvant, adjuvant and peri-adjuvant settingsUtilizing both mono & combination approaches CM-816: Neo-adjuvant nivo + chemo 80 ANVIL Adjuvant Opdivo CM -77T Peri-adjuvant CM -73LStage 3 unresectable CM -816 Neo-adjuvant Opdivo + chemo 2.2%d OR = 13.94 (99% CI, 3.49–55.75)cP < 0.0001 Differencec21.6% 24.0%d n/N 43/179 4/179 ITT (ypT0N0)b 2) Clinically meaningful EFS data in-house; to discuss with health authorities 1) Primary endpoint of pCRa met vs chemo Multiple opportunities in early-stage lung Oncology

Next novel I-O combination: relatlimab + nivolumab 81 LAG-3 and PD-1 are distinct immune checkpoints, often co-expressed on tumor-infiltrating lymphocytes, and contribute to tumor-mediated T-cell exhaustion1,2In preclinical models, LAG-3 and PD-1 blockade demonstrated synergistic antitumor activity1 APC, antigen-presenting cell; MHC, major histocompatibility complex; TCR, T-cell receptor.1 Woo S-R, et al. Cancer Res 2012;72:917–927; 2 Anderson AC, et al. Immunity 2016;44:989–1004 Clinical data support potential opportunities in melanoma (PDUFA: Mar 19, 2022) & beyond RELA + NIVO (n = 355) NIVO(n = 359) Median PFS, months 10.12 4.63 (95% CI) (6.37–15.74) (3.38–5.62) HR (95% CI) 0.75 (0.62–0.92) P value 0.0055 RELATIVITY-047 in 1L mel Oncology

Rela + Nivo FDC: broad expansion program 82 Melanoma NSCLC 1L – Relativity -047 Adjuvant (Stage 3/4): CA 224-098 rela+nivo vs nivo 1L: CA224 -095 rela+nivo+chemo vs pembro+chemo HCC 1L: CA224 -106 rela+nivo+bev vs nivo+bev 2L IO naïve: CA224 -073rela+nivo vs nivo 1L: CA224 -104 rela+nivo+chemo vs nivo+chemo In regulatory review (PDUFA: Mar 19, 2022) Registrational study POC to trigger registrational study Planned; not yet enrolling Ability to leverage ongoing data generation to inform future expansion opportunities CRC 2L+: CA224 -123rela+nivo vsregorafenib Oncology

Pegylated IL-2 partnered with NEKTAR Therapeutics Bempeg: additional next generation I-O opportunity 83 Melanoma Renal Adjuvant Mel: PIVOT-12nivo+bempeg vs. nivo2Readout: 2025 Bladder Peri-Surgical MIBC: CA045-009 nivo+bempeg vs. nivo vs. SOC1Readout: 2023 1L cis-ineligible: PIVOT-10nivo+bempeg2Readout: 1H 2022 1BMS operationalized; 2 NKTR operationalized 1L Mel: CA045-001nivo+bempeg vs. nivo1Readout: 1H 2022 1L RCC: PIVOT-09nivo+bempeg vs. TKI2Readout: 2H 2022 Note: CDP also includes earlier solid tumor studies (e.g., PIVOT-02), regional studies (e.g., Japan ‘010, China ‘016), and pediatric studies (e.g., ‘020) not depicted here. Ongoing registrational opportunity Oncology

MORAb-202 is a novel folate receptor alpha ADC 84 Differentiated payload (eribulin) Demonstrated single agent clinical activity across multiple tumor types In partnership with EisaiTumors of interest include ovarian, NSQ NSCLC, breast, endometrialHigh addressable population based on range of FR expression Development plan Interim analysis of Phase I study ongoing in Japan ORR*3: 46%DCR*4: 82%(RECIST v1.1*5) Expansion cohort is ongoing in FRα positive platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC) Percentage of change from baseline (%) Breast Endometrial NSCLC Ovarian Fallopian tube Next stepsEvaluating dose range to optimize therapeutic index Potential to further diversify solid tumor portfolio & extend leading position in Oncology Oncology

Phase 1 Phase 2 Phase 3 Marketed Robust Oncology Pipeline Anti-Fucosyl GM1 Anti-OX40 STING Agonist Anti-NKG2A motolimod Anti-TIM3 Anti-CTLA-4 NF Anti-CCR8 Anti-CTLA-4 Probody AR LDD CD3xPSCA(GEMoaB)2 Anti-IL-8 Anti-TIGIT relatlimab1 bempegal-desleukin linrodostat TGFβ Inhibitor LSD1 Inhibitor1 BET Inhibitor1(CC-90010) AHR Antagonist(Ikena)2 IL-12 Fc Anti-CTLA-4 NF-Probody TIGIT Bispecific farletuzumab - eribulin ADC subcutaneous nivolumab >20 assets in Phase 1 / 2 1 In development for solid tumors and hematology2 BMS has an exclusive option to license and/or option to acquire 85

Multiple promising early assets across immune-mediated diseases Foundation in Immunology today Expansion opportunities underway Building an exciting pipeline in Immunology Rheumatology / Gastroenterology / Dermatology (CD) 86 (MS,UC) Immunology deucravacitinib cendakimab

DeucravacitinibA first-in-class selective TYK2 inhibitor in moderate-to-severe psoriasis, with proven differentiation Deucravacitinib has potential to become new oral standard of care in psoriasis 87 Clinically meaningful efficacySuperior to apremilast, comparable to1st generation biologicsDurable responses through one yearFavorable safety and tolerability Consistent with its mechanism of action Opportunity for broad applicability across a range of immune-mediated diseasesFiled in U.S. & EU (PDUFA Sept 2022) Immunology

Missing data were imputed using nonresponder imputation.sPGA response defined as a score of 0 or 1, with ≥2-point improvement from baseline.PASI, Psoriasis Area and Severity Index; PASI 75, ≥75% reduction from baseline in PASI; PASI 90, ≥90% reduction from baseline in PASI; PASI 100, 100% reduction from baseline in PASI; sPGA 0/1, static Physician’s Global Assessment score of 0 or 1. Long-term data further support differentiated efficacy profile 1 2 65.1% 44.0% 19.3% 58.4% 35.5% 14.2% PASI 75 PASI 90 PASI 100 53.6% 17.5% 1 2 sPGA 0/1 sPGA 0 52.7% 23.5% Primary endpoint Primary endpoint PASI 75, PASI 90, PASI 100 responses for deucravacitinib (n=332) Meaningful responses sustained through wk 52 across primary & secondary endpoints sPGA 0/1 and sPGA 0 responses for deucravacitinib (n=332) 88 Not for Product Promotional Use Immunology

Labels for approved JAK 1,2,3 inhibitors reflect known JAK lab signature tofacitinib upadacitinib baricitinib MOA(in vitro JAK 1-3 selectivity) JAK 1, 2, 3 JAK 1, 2 Anemia (Hemoglobin) Do not initiate in pts with< 9 g/dLInterrupt in pts with < 8 g/dL or decrease of >2 g/dLMonitoring for potential changes Do not initiate in pts with < 9 g/dLInterrupt in pts with < 8 g/dL Decreases to < 8 g/dL were reported in clinical studiesMonitoring for potential changes ALT/AST (Liver Enzyme) Increased incidence of liver enzyme elevationRoutine monitoring of liver tests recommended Lipids Increases in total cholesterol, LDL, & HDLRoutine monitoring recommended 89 Note: Tofacitinib: maximum effects within 6 weeks; dose dependent increases in total cholesterol, LDL, HDL Immunology

Results through one year confirm no clinically meaningfulchanges from baseline and no JAK-like signature across lab results Graphs display as observed data for patients randomized to deucravacitinib at baseline in PSO-1 who continued treatment until Week 52.LLN, lower limit of normal; QD, once daily; ULN, upper limit of normal. 90 8 16 0 24 52 Total Cholesterol ULN LLN Mean ± SD, mg/dL 1 2 4 8 12 16 0 20 24 28 32 36 40 44 48 52 LLN ULN ALT Mean ± SD, U/L Mean ± SD, g/dL Hemoglobin 1 2 4 8 12 16 0 20 24 28 32 36 40 44 48 52 LLN ULN Platelets ULN Mean ± SD, 109/L 1 2 4 8 12 16 0 20 24 28 32 36 40 44 48 52 Weeks Weeks Weeks Weeks LLN Immunology

Deucravacitinib Ph 3 study ongoing in Psoriatic Arthritis 91 Data from Phase 2 Primary endpoints:ACR20Secondary endpoints included:DAS28-CRPHAD-DI (disability index questionnaire)PASI-75 Phase 3 Program (moderately to severely-active PsA) Deucravacitinib in Psoriatic Arthritis (PsA) Deucravacitinib demonstrated significantly greater ACR20 responses at wk 16: 52.9% (at 6 mg) vs 31.8% (placebo) IM011-054 IM011-055 Nominal P values for pairwise comparison vs placebo. P values in time course are for odds ratios obtained using a stratified Cochran-Mantel-Haenszel test with stratification factors (body weight and prior TNFi use) per randomization. Missing data were reported using NRI. *P = 0.0108 (12 mg). †P = 0.0021 (6 mg); P = 0.0021 (12 mg). ‡P = 0.0134 (6 mg); P = 0.0004 (12 mg). ACR20, American College of Rheumatology, 20% improvement in response; ITT, intent to treat; NRI, nonresponder imputation; QD, once daily; TNFi, tumor necrosis factor inhibitor.Included with permission from Mease PJ et al. Poster presentation at ACR Convergence 2020; November 5-9, 2020; Poster L03. 1 ACR20 at Week 16 (ITT, NRI) p = 0.0004 p = 0.0134 Placebo Deucravacitinib6 mg QD Deucravacitinib 12 mg QD Readout: 2024 Immunology

Opportunity to evaluate the potential for deucravacitnib in two important inflammatory bowel diseases Ulcerative ColitisInitial Ph2 study in moderate-to-severe UC (LATTICE-UC) did not meet primary & key secondary endpointsSecond Ph2 trial (IM-024-127, below) to assess potential at higher dose, with opportunity to expand – data expected 2022/2023 92 Crohn’s DiseaseOngoing Ph2 in Crohn’s Disease (LATTICE-CD)Data expected 2022/2023 Rollover LTE study DeucravacitinibDose 1 DeucravacitinibDose 2 Placebo R Open-Label Deucravacitinib Week 0Endoscopy/Biopsy Week 12Primary endpointEndoscopy/Biopsy Week 52Endoscopy/Biopsy Screening Double-Blind Treatment Period Open-Label Treatment Period 4 weeks 12 weeks 40 weeks Follow-Up 4 weeks No: Discontinue IP & enter post-treatment follow-up DeucravacitinibDose 1 DeucravacitinibDose 2 Placebo R Week 0Endoscopy/Biopsy Week 12Primary endpointEndoscopy/Biopsy Week 52Endoscopy/Biopsy Screening Induction Period Maintenance Period 28 days 12 weeks 40 weeks Clinical response at week 12 No: Switch to OL arm OL Deucra-vacitinib Clinical response at Wk 26 YES: Treat-throughDeucravacitinib YES: Treat-throughDeucravacitinib YES: Treat-throughPlacebo OL Deucra-vacitinib YES: Continue on OL arm Loss of response Immunology

Additional expansion opportunities for deucravacitinib 93 Psoriatic Arthritis Registrational Ongoing Ph 2 POC Psoriasis Systemic Lupus Erythematosus Crohn’s Disease Ulcerative Colitis Filed in U.S. & EU IM-011-127 Phase 2expected 2022/2023 Phase 3 enrolling; Readout: 2024 Readout: Early 2022 Readout: 2022/2023 Discoid Lupus Erythematosus Readout: 2H 2023 Psoriasis topical (Mild-to-moderate) Phase 2 to begin mid-2022 Dermatology Rheumatology Gastroenterology New Ph 2 POC Ability to leverage ongoing data generation to inform future expansion opportunities Immunology

Established IBD presence with Zeposia UC,with potential expansion to Crohn’s Disease 94 Primary endpoints:Induction studies: Week 12 clinical remissionMaintenance study: Co primary @ Week 52 clinical remission and endoscopic response Crohn’s Ph 3 Study Design (YELLOWSTONE) Zeposia in IBD Zeposia Placebo Zeposia Placebo Zeposia responders or remitters are re-randomized 1:1 to Zeposia or Placebo Zeposia Placebo 52 wk maintenance study Study 3201 Study 3202 N = 400 N = 200 N = 400 N = 200 12 wkinduction study Adults with moderately to severely active CD Ulcerative Colitis — Currently approved in the U.S.; positive CHMP opinion Zeposia currently provides UC patients with efficacy comparable to biologics, and a favorable safety profile in an oral medicine Provides opportunity to benefit additional patients living with IBDReadout: 2024 Crohn’s Disease — Phase 3 trial enrolling Immunology

EoE Overview:High unmet need, currently no approved therapiesLife altering disease for ~700k pts (combined U.S./EU5) EoE: POC established with Ph2 data Continuing to build with cendakimab High affinity IL-13 neutralizing antibody 95 IL-13Ra1 IL-13Ra2 Fibrosis & Remodeling IL13 IL13 Inflammation X X Cendakimab Binds to IL-13 ligandInhibits IL-13Ra1 & IL-13Ra2 subunitsPotential to address both inflammation & fibrosis/remodeling Co-primary (week 24):Change in dysphasia days% of pts with esophageal eosinophils ≤ 6/hpf Key secondary:% of pts with esophageal eosinophils ≤ 15/hpfEREFSEoE-HSS; mDSD composite score Ph 2 Atopic Dermatitis POC underway EoE: Currently enrolling Ph3 study; readout: 2024 Significant reduction in eosinophil count;Wk 16 @ 360mg: 122.6 (baseline) to 25.5 cells/hpfSignificant endoscopic improvement (EOE-EREF);Wk 16 @ 360mg: 9.4 (baseline) to 4.8 Immunology

Emerging Immunology Pipeline 96 Phase 1 Phase 2 Phase 3 Marketed Imm. Tolerance (Anokion)1 MK2 inhibitor branebrutinib IL2-CD25 iberdomide S1PR1 Modulator deucravacitinib cendakimab Anti-CD40 afimetoran (TLR 7/8 inhibitor) TYK2 inhibitor 1 BMS has an exclusive option to license and/or option to acquire

Advancing the pipeline across all therapeutic areas CardiovascularMavacamten EXPLORER LTE presentationMilvexian TKR Ph 2 positive data OncologyAdvancement of Opdivo expansion programsRela+Nivo FDC PDUFA dateMarch 19, 2022 HematologyCELMoDs new combination dataBreyanzi TRANSFORM data Immunologydeucravacitinib filed in U.S. & EU; PDUFA Sept 2022 97

deucravacitinib PsO EU approval PsA Ph3CD & DLE Ph2 (POC)2nd Ph2 in UC IM011-127 PsA Ph3 CD & DLE Ph2 (POC) cendakimab EoE Ph3 Zeposia CD Ph3 Induction/Maintenance mavacamten HFpEF Ph2 EMBARK (POC) Opdivo (+/- Yervoy) Metastatic: 1L ESCC (CM-648) approvalEarly-stage: Neo-adj lung EFS (CM-816) approval relatlimab 1L melanoma approvalInitiation Ph3 1Llung (CA224-095) bempeg 1L melanoma/1L renal/1L bladder Breyanzi 3L+ LBCL EU approval3L+ CLL (TRANSCEND-CLL) Ph2 98 2022 Key Milestones Multiple exciting milestones ahead 2023/2024 Key Milestones Opdivo (+/- Yervoy) Metastatic:1L CRPC (CM-7DX)1L HCC (CM-9DW)Early-stage:Adj. HCC (CM-9DX)Adj. RCC (CM-914)Peri-adj Lung (CM-77T)Peri-adj MIBC (CM-078)Adj. NSCLC (ANVIL,Co-op group) Milestones represent data read-outs unless otherwise specifiedTo be expanded to include regulatory milestones pending future registrational successes Abecma 2L+ MM (KarMMa-2) Ph2 (POC) CC-92480 4L+ MM Ph1/2 deucravacitinib PsO U.S. approvalSLE Ph2 (POC) cendakimab AD Ph2 (POC) mavacamten oHCM approvalSRT (VALOR) Ph3Initiation of Ph3 in nHCM milvexian SSP Ph2 (POC) relatlimab 2L HCC (POC) bempeg Neo-adj. CIS-ineligible MIBC Breyanzi 3L+ FL TRANSCEND Ph2 Abecma 3L+ MM (KarMMa-3) Ph3 CC-93269 Initiation of pivotal trial iberdomide Initiation of NDMM Ph3 H2H vs. Rev CC-92480 Initiation of Ph3 triplet 2L+ MM (w/ Vd, Kd) Reblozyl 1L MDS (ESA naïve) COMMANDS Ph3MF INDEPENDENCE Ph3

Program will reconvene following a short break (10 min)

Chris BoernerChief Commercialization Officer Commercial Opportunities

Building blocks of our Continuing Business deucravacitinib $3B+ $4B+ Key in-line growth drivers Key pipeline $1B+ mavacamten rela+nivo FDC Broad New Product Portfolio with significant non-risk adjusted revenue* potential in 2029 + Expansion opportunities across multiple assets milvexian BCMA TCE cendakimab bempeg iberdomide MORAb-202 CC-92480 101 *subject to positive registrational trials and health authority approval

In-line growth drivers contribute $8B to $10B growth from 2020-2025 $8.7B 2020 Combined SalesContinued growth opportunity: 102 Drive leadershipin NOAC class ExpandNOAC class Increasetreated population A standard of care across 11 tumors $9.2B 2020 SalesContinued growth opportunity: Maintain leadership in Melanoma & RCC Expand in metastatic disease incl. Lung & GI Lead evolution inearly-stage disease Enabled by strong cardiovascular infrastructure

Milvexian Ability to extend leadership in thrombotic diseases with milvexian 103 Building upon history of successful partnerships in CV Peak global sales:$7.1B (2011) FY global sales:$9.2B (2020) Potential to widely span arterial & venous diseasesOpportunity to launch prior to Eliquis LOE in 20281 Potential next-generation anti-thrombotic 1 In the U.S.: Subject to additional appeals and challenges

Mavacamten is the first therapeutic candidate to target the heart muscle proteins… with the intent of correcting the abnormal function of the heart.” Positive feedback from cardiologists on mavacamten 104 Physicians recognize a need for options that address underlying disease vs. treat symptomsDesire by patients & physicians to improve cardiac function and quality of life Unmet need The extraordinary data from the EXPLORER pivotal trial confirm mavacamten’s ability to relieve dynamic outflow obstruction, control symptoms and improve quality of life in patients” Dr. Iacopo Olivotto, M.D.Careggi Univ. & lead investigator, EXPLORER-HCM “ “ Mavacamten perception Mava targets the underlying pathophysiology of the condition, unlike other treatment methodsRecognition of magnitude of improvement in efficacy measures Dr. Daniel Jacoby, M.D.Yale School of Medicine

$4B+ 2029 NRA sales potential for mavacamten 105 HCM patient population 1.3M patients1 Significant HCM pts with obstructive disease (requiring chronic treatment) 60-70% >$4B Opportunity to drive significant penetration with a strong profile based on EXPLORER + nHCM & additional expansion indications NRA salesin 2029: No current treatment that treats underlying conditionNo differentiated competitors on horizonConcentrated prescriber base at launch Favorable landscape 1U.S./EU5 market prevalenceNRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approval Opportunity to increase diagnosis rate over time 20-25% Roughly double Future % Pts Symptomatic 60-80% Today

Deucravacitinib’s differentiated profile in psoriasis resonates with dermatologists 106 Based on interview & survey responses for POETYK data in psoriasis: MOARecognized as novel EfficacyViewed as compellingComparable to first-generation biologicsSuperior to current oral therapy SafetyTolerable, with favorable safety profileViewed as differentiated from JAK inhibitorsNo lab monitoring requirement is an important feature Once-daily dosingPerceived as more convenientthan current SOC

Topicals* Current Orals** ~1.9M Patients ~0.4M Patients Source: Decision Resources Group PsO Report; Symphony Health Claims data 2020 (US); BMS Internal Estimates Note: Numbers indicate patients on any prescribed treatment (systemic, topical, advanced) in G7 countries *Includes patients treated with Topicals and Phototherapy only**Orals include Otezla, Methotrexate, Cyclosporine and di-methyl fumarate (Mainly in Germany) Superior efficacy vs OtezlaDurable responses through 1 yearFavorable safety & tolerabilityEase of initiation Injectables ~0.4M Patients Deucravacitinib’s superior profile positioned to become oral of choice in psoriasis & may accelerate switch from topicals 107 Deucravacitinib

Significant sales potential in moderate-to-severe psoriasis 108 Large patient population ~3M patients1 Opportunity to expand systemic oral market By ~10% e.g., through earlier discontinuation of topicals Opportunity to establish oral-of-choice Biologic-like efficacy superior to existing oral SoCFavorable safety and tolerability profiledifferentiated from JAK inhibitorsbetter GI profile compared to existing oral SoC 1Represents combined U.S./EU5 patient prevalence numbers

109 $4B+ 2029 NRA opportunity to treat patients with immune-mediated diseases with deucravacitinib Opportunity to become oral of choice in mod-to-severe PsO Broaden into Rheumatology, GI & beyond >$4B NRA salesin 2029 +2M Pts IBD Mod-Severe(UC/CD) +1M Pts +2M Pts Psoriatic Arthritis ~3M Pts Psoriasis (Moderate-to-Severe) Lupus NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approval

Reblozyl has $4B+ non risk adjusted sales potential in 2029 Currently approved inTransfusion dependent beta-thal2L RS+ MDS 110 Potential expansion opportunities:1L MDS with COMMANDSMF and others Opportunity to drive growthin current indications:Increase share in ESA refractory populationIncrease adherenceMore frequent monitoring & earlier switching from ESA failures (NCCN update) NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approval

Important opportunity to establish Reblozyl in 2L RS+ MDS 111 Patient population ~8K patients1 Demonstrated repeated periods of transfusion independence ~50% of patients may not respond to ESAs2; there is potential to treat appropriate patients sooner ESA retreatment Increase adherence Drive adoption Establish a post-ESA standard of care profile Address patients earlier in their treatment journey with continued education 1Represents combined U.S./EU5 patient incidence numbers for 2L Lower Risk MDS RS+2NCCN Guidelines define no response as a lack of 1.5 gm/dL rise in hemoglobin or lack of a decrease in RBC transfusion requirement by 6 to 8 weeks of treatment.

112 $4B+ non risk adjusted opportunity with Reblozyl in 2029 Expansion into 1L MDS Establishment of novel MoA Entry into adjacent disease areas Notes regarding patient #s: MF & MDS represent combined U.S./EU5 estimates; beta-thal represents U.S. only; noted for each indication in launch year for lead market (e.g. U.S.); patient #s do not include growth of epidemiology over timeNRA = Non-Risk Adjusted Sales, subject to positive registrational trials and health authority approval1 Lower risk MDS patients +9K Pts Myelofibrosis +19K Pts 1L MDS1 Beta-thal 2L RS+ MDS1 ~8K Pts ~14K Pts ~6K Pts >$4B NRA salesin 2029

$3B+ Non risk adjusted sales potential in 2029 113 Opportunity to become the oral SOC in UC:Focused on increasing trialists & experienceStep wise approach to growing & broadening access over time Potential expansion opportunity:Further build presence in IBD with Crohn’s disease NRA: Non-Risk Adjusted Sales subject to positive registrational trials and health authority approval Currently approved in:MS: #1 S1P modulator in written RxUC: U.S. launch going well; positive CHMP opinion in EU

Significant expansion opportunities for Zeposia in UC 114 Large patient population ~1.1M patients1 Expand oral market Drive share of oral market Establish a new oral SOC, as first S1P modulator with strong profile: Biologic-like efficacy with favorable safety & tolerability profileNo black box warning Stepwise plan to grow access Build demandExpand accessConvert to commercial dispense 1Represents combined U.S./EU5 patient diagnosed prevalence numbers; moderate to severe ~8% ~20% Future Today Growing oral category over time at the expense of biologics

Establish Zeposia as the oral standard of care in UC 115 2021 2022 2023 Establish awareness and acceptance of new MOAEstablish breadth & depth of trialists with differentiated oral risk/benefit profile Elevate patient on-boarding capabilities (e.g., patient services) Broaden accessAccelerate share uptake by establishing new class as standard of carePatient engagement Expand access tofirst lineIncrease market growth by reaching uncontrolled patients on conventional therapies Launch integrated strategies reinforcing long-term data

Ongoing expansion into UC Foundation in MS $3B+ NRA opportunity to expand Zeposia into Crohn’s Disease over time 116 Broaden into CD +0.9M Pts +1.1M Pts Crohn’s disease (Moderate-to-Severe) Ulcerative Colitis (Moderate-to-Severe) Multiple Sclerosis >$3B NRA salesin 2029 0.9M Pts Note: Patient #s represent combined U.S./EU5 estimates, noted for each indication in launch year for lead market (U.S.); does not include growth of epidemiology over time NRA: Non-Risk Adjusted Sales subject to positive registrational trials and health authority approval

Well positioned to unlock the full potential of Cell Therapy 117 Leading oncology company with a track record of delivering Financial flexibility to invest in current products and next generation technologies Scale & Experience to realize potential Favorable Market Dynamics Strong demand & physician awareness U.S. market primed for outpatientPositive trends in access and reimbursement Unprecedented outcomes TRANSFORM 2L LBCL further validates approach and shows the transformative nature of Cell Therapy BMS is the only company with approved first-in-class or best-in-class products for two distinct targetsAdvancing next generation technologies Leading Innovation

Breyanzi has opportunity to grow into new indications & move up in treatment paradigm Expand into earlier lines Enter DLBCL Broaden into other indications >$3B NRA salesin 2029 118 ~18K Pts +22K Pts +13K Ptsc +19K Pts 2L CLL 3L+ CLL 2L+ LBCL 3L+ LBCL 3L+ iNHL +22K Pts Note: Patient #s represent combined U.S./EU5 estimates, noted for each indication in launch year for lead market (U.S.); does not include growth of epidemiology over time NRA: Non-Risk Adjusted Sales subject to positive registrational trials and health authority approval

$4B+ NRA opportunity with Rela+Nivo FDC, beginning in 2022 with metastatic melanoma 119 Source: Patient Epi from Decision Resources Group; 1 US 2021 patient estimates; includes 1L treated patients & early-stage treatable patients 2 1L Mel US treated patients ~10K, about one-third with IO monos; 3 Early-Stage Mel US treatable patients ~17K; 4 1L NSCLC US treated patients ~106K Phase 3opportunity inadjuvant melanoma + Opdivo + Yervoy PD-1 monotherapy BRAF MT Near-term focus in metastatic melanoma Near-term launch opportunity with Rela+Nivo FDC: Additional opportunities: NSCLC HCC CRC Ongoing data generation can inform future expansion opportunities Not for Product Promotional Use NRA: Non-Risk Adjusted Sales subject to positive registrational trials and health authority approval

Multiple additional opportunities across therapeutic areas Key pipeline $1B+ NRA sales in 2029 + additional expansion opportunities across multiple assets BCMA TCE cendakimab bempeg iberdomide MORAb-202 CC-92480 milvexian Cardiovascular Immunology Oncology Hematology 120 NRA: Non-Risk Adjusted Sales subject to positive registrational trials and health authority approval

David ElkinsChief Financial Officer Financial Overview

Confidence in our future 122 Strong innovation engine with deep scientific expertise to replenish the portfolioIndustry leading commercial capabilities to maximize growth by reaching more patients with unmet medical needs Strong execution provides confidence to deliver the full potential of our commercial brands and future pipeline & reinforces ability to navigate upcoming LOEsFinancial strength and flexibility to further strengthen the portfolio and provide healthy return of capital to shareholders

Opdivo (+/- Yervoy) U.S./EU expected approvals:1L RCC (9ER) , 1L GC (649, O+Chemo), adj Eso (577) adj MIBC (274) 1L Esophageal (CM-648) Opdivo return to annual growth Relatlimab 1L Melanoma w/ Opdivo Ph3 Breyanzi 3L+ DLBCL U.S. / EU approval3 2L TE and TNE DLBCL 3L+ CLL3 Abecma 4L+ MM U.S.1 / EU approval Iberdomide + dex 4L+ MM Ph 1b/2a Deucravacitinib PsO (2nd study) Ph3 & U.S. filing UC Ph2 (POC) Zeposia UC U.S. / EU approval Cendakimab Initiation of Ph3 Factor XIa inh. Total Knee Replacement VTEp Ph2 (POC) Mavacamten oHCM U.S. filing & approval2 Opdivo (+/- Yervoy) Metastatic1L HCC (CM-9DW) AdjuvantNeo-adj Lung EFS (CM-816)Peri-adj Lung (CM-77T) Bempeg 1L melanoma3 & 1L renal Breyanzi 3L+ Follicular lymphoma Abecma 3L+ MM (KarMMa-3) Ph3 2L+ MM (KarMMa-2) POC CC-92480 4L+ MM Ph1/2 CC-93269 (TCE) Initiation of pivotal trial Deucravacitinib PsO U.S./EU approval CD & Lupus Ph2 (POC) Zeposia CD Ph3 Factor XIa inh. Secondary Stroke Prevention Ph2 (POC) Reblozyl 1L MDS (ESA naïve) COMMANDS Ph3 Ph 1/2 Pipeline >20 POC decisions 123 2021 Key Milestones BMS continues to execute against our commitments 2020-2025:Low to mid-single digit revenue CAGR*Low double-digit revenue CAGR for Continuing business*Operating margins low to mid 40%s**~$3B of synergies by end of 2022$45B - $50B of free-cash flow 2021-2023** Financial Expectations 2022/2023 Key Milestones To be expanded to include regulatory milestones pending future registrational successes Not for Product Promotional Use On track based on 2021 guidance 1Approved after 4 prior lines of therapy2 PDUFA January 28, 20223 Expected in 2022 *At constant exchange rates – Non-GAAP: there is no reliable or reasonable estimable comparable GAAP metric for this Non-GAAP forward-looking information; **Non-GAAP: there is no reliable or reasonable estimable comparable GAAP metric for this forward-looking information

Strong execution reinforces our confidence in our financial targets 124 Strong Financial Foundation and Portfolio Positioned for Growth Operating Margins in low to mid-40s**~$3B of Synergies by end of 2022$45 – 50B of Free Cash Flow from 2021-2023 Low double-digit Revenue CAGR for Continuing Business 2020-2025*$25B+ NRA Revenue Potential in 2029 for Launch Brands Low to mid-single digit Revenue CAGR 2020–2025*Continuing Business ~90%of Total Revenue by 2025Launch Portfolio ~30% of Continuing Business by 2025 Total Company Growth & Revenue Profile Revenue Replacement Power Financial Strength *at constant exchange rates - There is no reliable or reasonable estimable comparable GAAP metric for this forward-looking information **Non-GAAP - There is no reliable or reasonable estimable comparable GAAP metric for this forward-looking informationNRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approval

Continued In-Line performance and New Product Portfolio more than offsets impact from near-term LOEs LOE Brands = Revlimid, Pomalyst, Sprycel, and Abraxane *At constant exchange rates – Non-GAAP. There is no reliable or reasonable estimable comparable GAAP metric for this forward-looking information ($12B–$14B) +$8B–$10B +$10B–$13B 2020 Revenues LOE Brands In-Line Brands Primarily I-O & Eliquis 2025 Revenues New Product Portfolio Growth 2020-2025Low to mid-single digit revenue CAGR* Continuing Business 2022: Expect revenue and Non-GAAP EPS growthBy 2025, expect $10-$13B risk-adjusted opportunity from new product portfolio 125

We expect New Product Portfolio to deliver $10B-$13B of risk-adjusted revenue in 2025 126 AbecmaOnuregInrebicrela+nivo FDC Significantly de-risked portfolio: 9 new products: 6 approved, 3 filedIncreased confidence in expansion opportunitiesZeposia launch in UCBreyanzi 2L+ LBCL deucravacitinib PsA Ph3 underway 2025: $10B-$13B Risk-adjusted sales Reblozyl 2L MDS Onureg AML Zeposia MS Breyanzi 3L+ LBCL Zeposia UC Abecma 5L+ mavacamten oHCM rela+nivo 1L Mel FDC deucravacitinib PsO Breyanzi 2L LBCL Zeposia CD Reblozyl 1L MDS Abecma 3-5L Breyanzi 3L+CLL Breyanzi 3L+ iNHL 2020 2021 2022 2023 2024 2025 Other deucrava Zeposia Breyanzi Reblozyl mavacamten

Path to maintaining Operating Margins 127 *Non-GAAP - There is no reliable or reasonable estimable comparable GAAP metric for this forward-looking information Low to mid-single digit Total Company Revenue CAGR from 2020 - 2025 Gross Margin decline tempered by growth in high-margin launch brands and I-O Operating expenses as % sales improves as revenue growth outpaces expense growth Operating Margins to remain in low to mid 40s through 2025*

Strong cash flow provides for tremendous financial flexibility 128 $45B - $50Bin free cash flow 2021-2023 *Future dividend payouts subject to board authorization Prioritizing Business Development to replenish and diversify the portfolio to drive long-term growth Strengthening the Balance Sheet to enable greater strategic and financial flexibility Returning cash to shareholders Continue to execute small & mid-sized bolt-on opportunities Reduction of debtMaintain strong investment-grade credit rating Continued dividend growth*Opportunistic share repurchase

Business Development remains a top priority to complement the portfolio for long-term growth 129 Deals over the last 18 months A further diversified pipeline Oncology Hematology Immunology Cardiovascular Neurology Financial Discipline Significant capacity for business development – strong rating & FCF generation Create value by leveraging leading capabilities in most strategic therapeutic areas Will continue to execute BD in leading scientific areas of high unmet medical need

Well positioned for future growth 130 Business continues to execute well against our financial and pipeline commitmentsStrong innovation engine for continued growth into the second half of the decadeConfident in our ability to address future LOEs Financial strength and flexibility to further strengthen the portfolio and provide healthy return of capital to shareholders New productsexpected to deliver $10B-$13B risk-adjusted revenue in 2025 Continued growthof new product portfolio $25B+ non-risk adjusted revenue* in 2029 Pipeline & business development targets focused in therapeutic areas with significant commercial potential *Non-Risk Adjusted revenue subject to positive registrational trials and health authority approval

Giovanni CaforioBoard Chair and Chief Executive Officer

Cardiovascular Opportunity for franchise durability and growth across all four key therapeutic areas Oncology Hematology Immunology 132 New Products Robust early-stage pipeline with 50+ assets in development deucravacitinib* rela+nivo FDC* bempeg iberdomide milvexian cendakimab Inline Brands Next Wave mavacamten* MORAb-202 (FRa ADC) CC-92480 BCMA TCE (CC-93269) * Subject to positive registrational trials & regulatory approval

deucravacitinib PsO EU approval PsA Ph3CD & DLE Ph2 (POC)2nd Ph2 in UC IM011-127 PsA Ph3 CD & DLE Ph2 (POC) cendakimab EoE Ph3 Zeposia CD Ph3 Induction/Maintenance mavacamten HFpEF Ph2 EMBARK (POC) Opdivo (+/- Yervoy) Metastatic: 1L ESCC (CM-648) approvalEarly-stage: Neo-adj lung EFS (CM-816) approval relatlimab 1L melanoma approvalInitiation Ph3 1Llung (CA224-095) bempeg 1L melanoma/1L renal/1L bladder Breyanzi 3L+ LBCL EU approval3L+ CLL (TRANSCEND-CLL) Ph2 133 2022 Key Milestones Multiple exciting milestones ahead 2023/2024 Key Milestones Opdivo (+/- Yervoy) Metastatic:1L CRPC (CM-7DX)1L HCC (CM-9DW)Early-stage:Adj. HCC (CM-9DX)Adj. RCC (CM-914)Peri-adj Lung (CM-77T)Peri-adj MIBC (CM-078)Adj. NSCLC (ANVIL,Co-op group) Milestones represent data read-outs unless otherwise specifiedTo be expanded to include regulatory milestones pending future registrational successes Abecma 2L+ MM (KarMMa-2) Ph2 (POC) CC-92480 4L+ MM Ph1/2 deucravacitinib PsO U.S. approvalSLE Ph2 (POC) cendakimab AD Ph2 (POC) mavacamten oHCM approvalSRT (VALOR) Ph3Initiation of Ph3 in nHCM milvexian SSP Ph2 (POC) relatlimab 2L HCC (POC) bempeg Neo-adj. CIS-ineligible MIBC Breyanzi 3L+ FL TRANSCEND Ph2 Abecma 3L+ MM (KarMMa-3) Ph3 CC-93269 Initiation of pivotal trial iberdomide Initiation of NDMM Ph3 H2H vs. Rev CC-92480 Initiation of Ph3 triplet 2L+ MM (w/ Vd, Kd) Reblozyl 1L MDS (ESA naïve) COMMANDS Ph3MF INDEPENDENCE Ph3

Well positioned for the near-term and long-term 135 Confident in our ability to navigate upcoming LOEs Strong position to grow and renew our business Strong cash flow and balance sheet strength support ability to execute disciplined business development Significant growth potential from new product portfolio Exciting pipeline with differentiated firstand/or best-in-class assets

Investor Meeting Q&A 136 Giovanni CaforioBoard Chair andChief Executive Officer Chris BoernerChief Commercialization Officer David ElkinsChief Financial Officer Samit HirawatChief Medical Officer,Global Drug Development Rupert VesseyPresident, Research & Early Development

Appendix

Hematology Fibrosis HSP47 LPA1 Antagonist Immunology Oncology Data as of November 16, 2021 Anti-Fucosyl GM1 Anti-OX40 TIGIT Bispecific Anti-NKG2A Anti-SIRPα1 AR LDD Anti-CTLA-4 NF Anti-CCR8 Anti-CTLA-4 Probody BCMA TCE CD3xPSCA(GEMoaB)2 IL-12 Fc Anti-IL-8 Anti-TIGIT BET Inhibitor(BMS-986158) CD19 NEX T BCMA ADC BCMA CAR T(bb21217) TGFβ Inhibitor LSD1 Inhibitor1 iberdomide 1 In development for solid tumors and hematology2 BMS has an exclusive option to license and/or option to acquire iberdomide MK2 Inhibitor Anti-CD40 IL2-CD25 Imm. Tolerance (Anokion)2 cendakimab branebrutinib deucravacitinib Cardiovascular FA-Relaxin FXIa Inhibitor 139 Phase 1 Phase 2 Phase 3 A/I CELMoD(CC-92480) A/I CELMoD(CC-99282) GSPT1 CELMoD(CC-90009) BET Inhibitor1(CC-90010) CD33 NKE CD47xCD20 Neuroscience Anti-Tau(Prothena)2 AHR Antagonist(Ikena)2 S1PR1Modulator afimetoran(TLR 7/8 Inhibitor) BET Inhibitor1(CC-95775) NME FPR-2 Agonist Active Clinical Development Portfolio STING Agonist danicamtiv BCMA NEX T motolimod Cardiac Myosin Inhibitor milvexian(FXIa Inhibitor) mavacamten TYK2 Inhibitor GPRC5D CAR T COVID-19 SARS-CoV-2 mAb Duo Anti-CTLA-4 NF-Probody CK1α CELMoD ROMK Inhibitor BTK Inhibitor BCMA NKE ROR1 CAR T Anti-TIM3 farletuzumab - eribulin ADC FAAH/MGLL Dual Inhibitor relatlimab1 bempegal-desleukin linrodostat subcutaneous nivolumab eIF2b Activator Marketed

140 Abbreviations ACC American College of Cardiology DLBCL Diffuse Large B-Cell Lymphoma MM Multiple Myeloma RR Relapsed Refractory ACR American College of Rheumatology DLE Discoid Lupus Erythematosus MR Minimal Response RS Ring Sideroblasts ACS Acute Coronary Syndrome EADV European Academy of Dermatology and Venereology MS Multiple Sclerosis SAE Serious Adverse Event AD Atopic Dermatitis EFS Event Free Survival MSI-H High Microsatellite Instability SC Subcutaneous ADC Antibody Drug Conjugate EoE Eosinophilic Esophagitis MTD Maximum Tolerated Dose sCR Stringent Complete Response Adj Adjuvant ESA Erythropoietin Stimulating Agents NE Not Evaluable SCT Stem Cell Transplant AE Adverse Event ESCC Esophageal Squamous Cell Carcinoma nHCM Non-Obstructive Hypertrophic Cardiomyopathy SD Stable Disease AFIB Atrial Fibrillation FDC Fixed Dose Combination NKE Natural Killer Cell Engager SLE Systemic Lupus Erythematosus AHA American Heart Association FL Follicular Lymphoma NRA Non-Risk Adjusted SoC Standard of Care AML Acute Myeloid Leukemia GAAP Generally Accepted Accounting Principles NRI Nonresponder Imputation sPGA Static Physicians Global Assessment AR-LDD Androgen Receptor Ligand Degrader GC Gastric Cancer NSCLC Non-Small Cell Lung Cancer SRT Septal Reduction Therapy ASH American Society of Hematology HCC Hepatocellular Carcinoma NSQ Nonsquamous SSP Secondary Stroke Prevention A-Thal Alpha Thalassemia HFpEF Heart Failure w/ Preserved Ejection Fraction NTD Non-Transfusion Dependent TCE T-Cell Engager BCMA B-Cell Maturation Antigen IBD Inflammatory Bowel Disease NYHA New York Health Association TD Transfusion Dependent BID Twice a Day IMiD Immunomodulatory Drugs OAC Oral Anticoagulant TE Transplant Eligible B-Thal Beta Thalassemia IND Investigational New Drug oHCM Obstructive Hypertrophic Cardiomyopathy TEAE Treatment Emergent Adverse Events CAD Coronary Artery Disease iNHL Indolent Non-Hodgkin's Lymphoma ORR Overall Response Rate TKR Total Knee Replacement CAGR Compound Annual Growth Rate I-O Immuno-Oncology PAD Peripheral Artery Disease TNE Transplant Non-Eligible CAR T Chimeric Antigen Receptor Therapy ITT Intent to Treat PASI Psoriasis Area and Severity Index TNFi Tumor Necrosis Factor Inhibitor CBR Clinical Benefit Rate LBCL Large B-Cell Lymphoma PD Progressive Disease UC Ulcerative Colitis CD Crohn’s Disease LOE Loss of Exclusivity PDUFA Prescription Drug User Fee Act VGPR Very Good Partial Response CELMoD Cereblon E3 Ligase Modulator LVOT Left Ventricular Outflow Tract POC Proof of Concept VTEp Venous Thromboembolism Prevention CLL Chronic Lymphocytic Leukemia mCRPC Metastatic Castration-Resistant Prostate Cancer PR Partial Response CR Complete Response MDS Myelodysplastic Syndrome PsA Psoriatic Arthritis CRC Colorectal Cancer mDSD modified Daily Symptom Diary PsO Psoriasis CRS Cytokine Release Syndrome Mel Melanoma QD Once Daily CTA Clinical Trial Application MF Myelofibrosis RCC Renal Cell Carcinoma DCR Disease Control Rate MIUC Muscle Invasive Urothelial Cancer RP2D Recommended Phase 2 Dose